Clinical-stage biopharmaceutical company developing targeted cancer therapies.
Zentalis Pharmaceuticals, Inc. is a pioneering clinical-stage biopharmaceutical firm dedicated to the discovery and advancement of small molecule therapeutics aimed at combating a wide spectrum of cancers. At the forefront of its pipeline is ZN-c3, an inhibitor targeting WEE1, a protein tyrosine kinase, currently undergoing Phase 2 clinical trials for advanced solid tumors. Additionally, ZN-c3 is being evaluated in Phase 1/2 trials both as a standalone treatment and in combination with chemotherapy for platinum-resistant ovarian cancer, with ongoing Phase 2 monotherapy trials focused on a tumor-agnostic, predictive biomarker.
The company's portfolio also features ZN-c5, an oral selective estrogen receptor degrader in Phase 1/2 trials for advanced estrogen receptor-positive, HER2-negative breast cancer and other related conditions. Another promising candidate, ZN-d5, a selective inhibitor of B-cell lymphoma 2, is undergoing Phase 1 trials targeting non-Hodgkin's lymphoma and acute myelogenous leukemia. Additionally, Zentalis Pharmaceuticals is advancing ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, through Phase 1/2 trials targeting advanced non-small cell lung cancer.
Innovating beyond traditional therapies, Zentalis Pharmaceuticals is developing BCL-xL heterobifunctional degraders that utilize E3 ligases not expressed in platelets, potentially mitigating dose-limiting thrombocytopenia associated with current BCL-xL inhibitors. The company's strategic approach is reinforced by licensing agreements and collaborations with esteemed entities such as Recurium IP Holdings, Mayo Foundation for Medical Education and Research, and major pharmaceutical firms like Pfizer, Eli Lilly, GlaxoSmithKline, and Zentera Therapeutics.
Founded in 2014 and headquartered in New York, New York, Zentalis Pharmaceuticals embodies a commitment to pioneering research and development in oncology. With a robust pipeline and strategic partnerships, the company ai ms to redefine treatment paradigms, offering hope to patients facing challenging cancer diagnoses worldwide.